SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending after reporting strong operational results that maintained full-year profit guidance despite geopolitical headwinds, bolstered by continued contract wins in their SMR and defense segments. The community remains focused on the company's long-term transformation into a high-margin industrial leader, with active discussions centering on the strategic value of its nuclear power initiatives and robust engine aftermarket performance.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is drawing significant investor attention due to intense volume and speculation regarding upcoming data center lease contracts, with the community closely tracking its performance on the TSX as a potential indicator of broader momentum. Enthusiasts are pointing to the company's power pipeline and Russell 3000 inclusion as key long-term catalysts, while many are actively debating how incoming AI-driven demand will impact the stock's valuation as they wait for formal partnership announcements.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401jK community is actively generating buzz through grassroots efforts, including IRL raids and viral meme campaigns that position the ticker as an alternative to traditional retirement plans. Enthusiasts emphasize the project's long-standing community-led development and upcoming NFT drops, contrasting these efforts against the perceived instability of legacy financial systems.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending as the community speculates on upcoming catalysts, including a major deployment on Ethereum and the rollout of a predictive allocation mechanism designed to optimize liquidity incentives. Investors are increasingly viewing the protocol as a core infrastructure play within the Base ecosystem, with many discussing its potential to capture significant volume as tokenized assets gain traction.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for intense community debate, as traders remain split between long-term holders betting on a future rally and critics dismissing it as a stagnant meme coin. Market sentiment is heavily divided, with active discussions focused on the coin's large supply, the role of broader market volatility, and comparisons to newer meme projects vying for liquidity.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

Investors are actively focusing on HHIS as they rotate out of certain U.S.-based yield ETFs to capitalize on Harvest's diversified Canadian-listed portfolio and tax-efficient monthly income. The conversation is further fueled by the recent launch of the SpaceX-focused ETF and ongoing community analysis of how underlying tech holdings influence the broader income-generating strategy.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

Fox Corporation is currently drawing investor attention as it manages significant volatility linked to its strategic pivot into digital streaming, underscored by its acquisition of Roku and ongoing efforts to capture a younger, streaming-native audience. The community is actively debating the merits of this aggressive expansion, with many investors weighing the long-term potential of its ad-tech infrastructure against concerns over increased debt and the broader industry shift away from traditional linear television.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor ongoing M&A speculation, with community discourse heavily focused on the company's potential interest in acquiring obesity-focused biotech assets like Viking Therapeutics to bolster its late-stage pipeline. Meanwhile, discussions around AbbVie's oncology portfolio remain heated, as some market participants compare the long-term potential of emerging biotech competitors against AbbVie's established drugs in the blood cancer space.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending following significant attention toward its role in post-quantum cryptography, specifically highlighted by recent research that cites its security framework. The community is actively debating whether this technical validation and increased institutional interest can drive a sustained price breakout, while many continue to focus on accumulation strategies despite conflicting views on the asset's long-term potential.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is attracting significant community attention due to its ongoing record-breaking price momentum, which retail and institutional investors link to its unique perpetuals-exchange fee structure and upcoming ETF developments. The community is actively discussing its potential to disrupt traditional exchange models as volume grows and adoption expands beyond standard crypto markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Dual Listing on NYSE Texas Caris Life Sciences Announces Dual Listing on NYSE Texas PR Newswire IRVING, Texas, June 16, 2026 IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and...

Caris Life Sciences Authorized Buy Back Up To $100 Mln

(RTTNews) - Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock...

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Announces Share Repurchase Program Caris Life Sciences Announces Share Repurchase Program PR Newswire IRVING, Texas, June 8, 2026 IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio...

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing PR Newswire IRVING...

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with...

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels Caris Life...

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure BloodBased Testing Authorization PR Newswire IRVING, Texas, May 8, 2026...

Caris Life Sciences Q1 Loss Narrows

(RTTNews) - Caris Life Sciences (CAI) on Thursday reported first-quarter results with revenue rising sharply from last year while losses narrowed, driven by strong growth in molecular profiling services...

Caris Life Sciences Reports First Quarter 2026 Financial Results

Caris Life Sciences Reports First Quarter 2026 Financial Results Caris Life Sciences Reports First Quarter 2026 Financial Results PR Newswire IRVING, Texas, May 7, 2026 Revenue growth of 79% driven...

UBS Group AG Raises Stock Position in Caris Life Sciences, Inc. $CAI

UBS Group AG lifted its stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Free Report) by 825.9% during the fourth quarter, according to the company in its most recent Form 13F filing with...

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

Caris Life Sciences Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.01	--	--	N/A
Q1 '26	-$0.02	$0.00	100.00%	BEAT
Q4 '25	$0.03	$0.28	723.07%	BEAT
Q3 '25	-$0.18	$0.08	145.67%	BEAT
Q2 '25	-$0.22	-$7.97	-3550.82%	MISSED

CAICaris Life Sciences Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CAI News